Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Kenneth Pennington"'
Autor:
Carol Young, Constantin T. Yiannoutsos, Cindy Stoner, Larry D. Cripe, Michael J. Stender, Paul Walker, Kenneth Pennington, Daniel A. Vaena, Anthony Stephens
Publikováno v:
Leukemia Research. 28:49-52
Topotecan has demonstrable activity in high-risk MDS and CMMoL. However, the significant toxicity of topotecan administered at a dose of 2 mg/m 2 i.v. daily for 5 days as a continuous infusion limits its use in older patients. Therefore, we studied t
Autor:
Gregory M. Springett, Edith P. Mitchell, Heather Horne, Allyson J. Ocean, David M. Goldenberg, William A. Wegener, Alberto J. Montero, John S. Kauh, Bekaii-saab Tanio, Max Sung, Kenneth Pennington, David V. Gold, Michael J. Guarino
Publikováno v:
Annals of Oncology. 23:iv5-iv6
Introduction Clivatuzumab (hPAM4) is a humanized monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. Methods Fractionated radioimmunotherapy (RAIT) with 90Y-labeled humanized mAb (90Y-hPAM4) plus Gem as
Autor:
William A. Wegener, Kenneth Pennington, Nick Teoh, Alberto J. Montero, Allyson J. Ocean, David V. Gold, David M. Goldenberg, Michael J. Guarino, Seza A. Gulec, Tanios Bekaii-Saab
Publikováno v:
Journal of Clinical Oncology. 29:240-240
240 Background: The90Y-labeled anti-mucin humanized mAb, clivatuzumab tetraxetan (90Y-hPAM4), is in clinical development in APC. A phase I/II trial of 90Y-hPAM4 with low-dose radiosensitizing Gem has now concluded 90Y-dose escalation. Methods: Pts wi
Autor:
Kenneth Pennington, William A. Wegener, David M. Goldenberg, Aldo N. Serafini, Charles J. Schneider, Michael J. Guarino, Kathiresan Suppiah, Robert M. Sharkey, David V. Gold, C. Rocha-Lima
Publikováno v:
Journal of Clinical Oncology. 27:4620-4620
4620 Background: In a phase I study, a single dose of 90Y-labeled anti-mucin humanized antibody, hPAM4 (90Y-hPAM4), led to several transient reductions or stabilization of lesions in advanced pancreatic cancer, with bone marrow toxicity limiting the
Autor:
D. Breutman, Kenneth Pennington, Seza A. Gulec, J. Wheeler, R. Hostetter, D. Schwartzentruber
Publikováno v:
Journal of Clinical Oncology. 26:15011-15011
15011 Background: Concurrent chemotherapy and radiation in colorectal cancer(CRC) can improve outcome of local or regional disease. This study is an attempt to derive a similar benefit using chemotherapy and a novel method of radiation therapy for pa
Autor:
W. B. Fisher, Lawrence H. Einhorn, Rafat Ansari, Richard C. Lauer, Kenneth Pennington, Patrick J. Loehrer
Publikováno v:
American Journal of Clinical Oncology. 11:634-635
The Hoosier Oncology Group (HOG) treated 13 patients with bronchogenic carcinoma with an innovative schedule of cisplatin and VP-16. Unexpected toxicity was noted, with five deaths secondary to granulocytopenia and septic shock and three episodes of